Neumora Therapeutics (NMRA) Total Liabilities (2022 - 2026)
Neumora Therapeutics (NMRA) posted quarterly Total Liabilities of $83.2 million for Q1 2026, up 193.11% year-over-year from $28.4 million in Q1 2025, and down 4.56% quarter-over-quarter from $87.2 million in Q4 2025.
Neumora Therapeutics (NMRA) Total Liabilities (2022 - 2026) Analysis & Trends
Neumora Therapeutics' Total Liabilities history runs 5 years deep, the most recent figure standing at $83.2 million for Q1 2026.
- In Q1 2026, Total Liabilities rose 193.11% year-over-year to $83.2 million; the TTM figure through Mar 2026 stood at $83.2 million (up 193.11% YoY), while the FY2025 annual figure was $87.2 million, up 191.48% from the prior year.
- Total Liabilities for Q1 2026 stood at $83.2 million, down from $87.2 million in the prior quarter.
- The five-year high for Total Liabilities was $87.2 million in Q4 2025, with the low at $23.2 million in Q2 2024.
- The 5-year median for Total Liabilities is $30.9 million (2024), against an average of $40.4 million.
- The sharpest annual moves came in 2023 and 2026: Total Liabilities decreased 7.75% in 2023, then soared 193.11% in 2026.
- Neumora Therapeutics' Total Liabilities stood at $29.4 million in 2022, then decreased by 7.75% to $27.1 million in 2023, then advanced by 10.28% to $29.9 million in 2024, then soared by 191.48% to $87.2 million in 2025, then retreated by 4.56% to $83.2 million in 2026.
- Business Quant data shows NMRA's Total Liabilities at $83.2 million in Q1 2026, $87.2 million in Q4 2025, and $45.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Neumora Therapeutics | 296.45 Mn | 296.45 Mn | - | 83.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 83.20 Mn |
| Dec 31, 2025 | 87.18 Mn |
| Sep 30, 2025 | 45.67 Mn |
| Jun 30, 2025 | 40.95 Mn |
| Mar 31, 2025 | 28.38 Mn |
| Dec 31, 2024 | 29.91 Mn |
| Sep 30, 2024 | 31.80 Mn |
| Jun 30, 2024 | 23.21 Mn |
| Mar 31, 2024 | 25.67 Mn |
| Dec 31, 2023 | 27.12 Mn |
| Sep 30, 2023 | 32.06 Mn |
| Dec 31, 2022 | 29.40 Mn |